NCT06489184尚未招募不适用
This is a Multicenter, Retrospective Real-world Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 490
- 试验地点
- 1
- 主要终点
- Progression Free Survival (PFS)
研究概览
简要总结
This is a Multicenter, Retrospective Real-world Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients aged ≥18 years old
- •Must have a confirmed diagnosis of Chronic Lymphocytic Leukemia (CLL) requiring treatment (iwCLL [International Workshop on Chronic Lymphocytic Leukemia] criteria)；
- •Treatment-naïve OR Refractory Recurrence CLL patients who were initiated on Zanubrutinib;
- •4.Prior or current use of Zanubrutinib for ≥3 months
- •5.At least one follow-up was recorded during Zanubrutinib treatment
排除标准
- 未提供
结局指标
主要结局
Progression Free Survival (PFS)
时间窗: up to two years
PFS is defined as the duration from date of Zanubrutinib initiation to date of disease progression (PD \[according to the physician's evaluation\]) or death from any cause
次要结局
- Overall Survival(up to two years)
- Time to Next Therapy (TTNT)(up to two years)
- Adverse Events(up to two years)
研究者
Xiao-Jun Huang
Prof.
Peking University People's Hospital
研究点 (1)
Loading locations...
相似试验
尚未招募
不适用
The Real World Study of BTK Inhibitor in the Treatment of Chronic Lymphocytic Leukemia in ChinaCLLNCT06557304Peking University People's Hospital1,000
尚未招募
不适用
the Real World Study of Orelabrutinib in the Treatment of CLL/SLLCLL/SLLNCT05975164Shandong University50
尚未招募
2 期
This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell LymphomaLymphoma, Mantle-CellLymphoma, Non-HodgkinNCT06427213Henan Cancer Hospital41
进行中（未招募）
3 期
A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of ZanubrutinibB-cell MalignanciesNCT04170283BeOne Medicines955
招募中
不适用
Pyrotinib Combined With Trastuzumab for Maintenance Therapy After First-line TH (P) Therapy for HER2+ABCHER2-positive Breast CancerNCT06754059zhangjie60